Refine by
Vaccine Targeting Equipment & Supplies In Qatar
11 equipment items found
Manufactured by:DSS Takara Bio India Pvt Ltd based inNew Delhi, INDIA
SARS-CoV-2 research is happening at breakneck speed, and scientists are trying to identify epitopes that could trigger an immune response to the virus, an important step in the development of novel vaccines. Takara Bio offers an array of innovative technologies to support this endeavor. The development of a vaccine involves an analysis of the viral and host ...
Manufactured by:Frontier Biotechnologies Inc. based inNanjing, CHINA
Licensed with exclusive rights for greater China from AFFiRiS AG, a clinical-stage biotechnology company in Austria, FB6001 is an investigational therapeutic peptide vaccine targeting PCSK9 to treat hypercholesterolemia. PCSK9 is a clinically validated target and FB6001 is a potential first-in-class immunotherapy for hypercholesteremia. FB6001 is ...
Manufactured by:EnGen Bio LLC based inREDWOOD CITY, CALIFORNIA (USA)
While it has been believed that M1 is completely protected by the lipid membrane, we have discovered that a portion of it is in fact exposed and accessible to monoclonal antibody binding, and therefore represents a vaccine target. We have determined that it is critical to engineer the immunogen to allow the immune system to focus its response on the ...
Manufactured by:Vitruvian BioMedical, Inc. based inAddison, TEXAS (USA)
VITRUVIAN has obtained the Exclusive Global License for a Therapeutic Vaccine for the Prevention of Alzheimer's Disease. YM7555 - Alzheimer’s Disease Therapeutic Vaccine targeting ABeta and TAU. VITRUVIAN has received an Exclusive Global License for YM7555 which is a Therapeutic Vaccine technology for the prevention of ...
Manufactured by:Virometix AG based inSchlieren, SWITZERLAND
Virometix is focusing on the development of vaccine candidates with broad protection against a diverse number of coronaviruses. Our epitope-focused SVLP-based vaccine aims to target specific regions of the Receptor Binding Domain (RBD) of the Spike protein. Proof-of-concept studies are currently ongoing using SARS-CoV-2, where five Synthetic ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines is developing a GeneVav prime/VesiculoVax™ boost therapeutic vaccine that targets all HCV genotypes for use as an adjunct to drug ...
Manufactured by:Auro Vaccines LLC based inPearl River, NEW YORK (USA)
Auro Vaccines has also developed a GeneVax prime/VesiculoVax boost therapeutic vaccine that targets all eight HBV genotypes for use as an adjunct to drug ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-008 is a multivalent lymph node–targeted AMP peptide vaccine developed to target p53 hotspot mutations. p53 is a tumor-suppressing protein that controls the cell cycle, DNA replication, and uncontrolled cell division during tumor growth.4 Mutations in the p53 protein lead to uncontrolled tumor progression and growth.4 ...
Manufactured by:Elicio Therapeutics based inBoston, MASSACHUSETTS (USA)
ELI-007 is a multivalent lymph node–targeted AMP peptide vaccine developed to target BRAF gene mutations. The BRAF gene is part of an intracellular signaling pathway that drives cell growth and division.1 BRAF mutations can lead to uncontrolled cell growth and ultimately cancer. BRAF mutations are present in multiple types of ...
Manufactured by:Hygieia Biological Laboratories based inWoodland, CALIFORNIA (USA)
Preventative health including vaccination is a key focus of good animal management. Hygieia offers inactivated autogenous bacterins and vaccines which are custom manufactured from disease agents specifically found at an individual ranch, zoo, or other animal facility. This allows the producer or owner to tailor a vaccine formulation to ...
by:NEC OncoImmunity AS based inOslo, NORWAY
Recent advances in the field of immuno-oncology have established that mutated antigens (neoantigens), are viable targets of the immune system, potentially specific to each individual cancer patient. This plus many other breakthroughs in immuno-oncology and the rapid advances in next generation sequencing (NGS), opens up exciting new opportunities to harness neoantigens for their therapeutic and ...